V
Varagur Venkatesan
Researcher at University of Western Ontario
Publications - 73
Citations - 5660
Varagur Venkatesan is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Radiation therapy & Prostate cancer. The author has an hindex of 29, co-authored 70 publications receiving 5063 citations. Previous affiliations of Varagur Venkatesan include Vassar College & Queen's University.
Papers
More filters
Journal ArticleDOI
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Marshall R. Posner,Diane Hershock,Cesar R. Blajman,Elizabeth Mickiewicz,Eric Winquist,Vera Gorbounova,Sergei Tjulandin,Dong M. Shin,Kevin J. Cullen,Thomas J. Ervin,Barbara A. Murphy,Luis E. Raez,Roger B. Cohen,Monica Spaulding,Roy B. Tishler,Berta Roth,Rosana del Carmen Viroglio,Varagur Venkatesan,Ilya Romanov,Sanjiv S. Agarwala,K. William Harter,Matthew Dugan,Anthony J. Cmelak,Arnold M. Markoe,Paul W. Read,Lynn Steinbrenner,A. Dimitrios Colevas,Charles M. Norris,Robert I. Haddad +28 more
TL;DR: Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisPlatin and fluoride induction chemotherapyplus cheMoradiotherapy.
Journal ArticleDOI
Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
Gerald E. Hanks,Thomas F. Pajak,Arthur T. Porter,David J. Grignon,Harmart Brereton,Varagur Venkatesan,Eric M. Horwitz,Colleen A. Lawton,Seth A. Rosenthal,Howard M. Sandler,William U. Shipley +10 more
TL;DR: The RTOG 92-02 trial supports the addition of LT adjuvant AD to STAD with RT for T2c-4 PC and in the exploratory subset analysis of patients with Gleason scores 8 to 10, LT adjUvant AD resulted in a survival advantage.
Journal ArticleDOI
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
Eric M. Horwitz,Kyounghwa Bae,Gerald E. Hanks,Arthur T. Porter,David J. Grignon,Harmar D. Brereton,Varagur Venkatesan,Colleen A. Lawton,Seth A. Rosenthal,Howard M. Sandler,William U. Shipley +10 more
TL;DR: A survival advantage for LTAD + RT in the treatment of locally advanced tumors with a Gleason score of 8 to 10 suggests that this should be the standard of treatment for these high-risk patients.
Journal ArticleDOI
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
Anthony C. Nichols,Julie A. Theurer,Eitan Prisman,Nancy Read,Eric Berthelet,Eric Tran,Kevin Fung,John R. de Almeida,Andrew Bayley,David P. Goldstein,Michael P. Hier,Khalil Sultanem,Keith Richardson,Alex Mlynarek,Suren Krishnan,Hien Le,John Yoo,S. Danielle MacNeil,Eric Winquist,J. Alex Hammond,Varagur Venkatesan,Sara Kuruvilla,Andrew Warner,Sylvia Mitchell,Jeff Chen,Martin Corsten,Stephanie Johnson-Obaseki,Libni Eapen,Michael Odell,Christina Parker,Bret Wehrli,Keith Kwan,David A. Palma +32 more
TL;DR: Patients treated with radiotherapy showed superior swallowing-related QOL scores 1 year after treatment, although the difference did not represent a clinically meaningful change, and toxicity patterns differed between the groups.
Journal ArticleDOI
Prostate volume contouring: A 3D analysis of segmentation using 3DTRUS, CT, and MR
Wendy Smith,C. Lewis,Glenn Bauman,George Rodrigues,David D'Souza,R. Ash,Derek Ho,Varagur Venkatesan,Donal B. Downey,Aaron Fenster +9 more
TL;DR: The contouring of prostates on CT, MR, and 3DTRUS results in systematic differences in the locations of and variability in prostate boundary definition between modalities.